ArticleJournal of contemporary psychotherapy2018
Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder.
Article in Journal of contemporary psychotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- MDMA and memory, addiction, and depression: dose-effect analysis.Psychopharmacology · 2022Pooled it
- Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA: A Randomized Clinical Trial.JAMA network open · 2025Trial
- A neurocognitive account of complex PTSD: self-modelling, affective dysregulation, and implications for MDMA-assisted and targeted psychotherapies.European journal of psychotraumatology · 2026Review
- Expert recommendations for Germany's integration of psychedelic-assisted therapy.BMC medical education · 2024Review
- The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.Current neuropharmacology · 2024Review
- Novel Mechanisms and Interventions for PTSD.Focus (American Psychiatric Publishing) · 2023Article
- A Review of MDMA-Assisted Therapy for Posttraumatic Stress Disorder.Focus (American Psychiatric Publishing) · 2023Review
- Coping motives mediate the relationship between PTSD and MDMA use in adolescents with substance use disorders.Addiction science & clinical practice · 2022Article
- 3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs.Frontiers in psychiatry · 2022Review
- A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy.Frontiers in psychiatry · 2022Review
- Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy.Journal of psychopharmacology (Oxford, England) · 2021Review
- Self-reported PTSD is associated with increased use of MDMA in adolescents with substance use disorders.European journal of psychotraumatology · 2021Article
- Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy.Frontiers in psychology · 2021Review
- Locomotor effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in mice: psychostimulant effects, stereotypy, and sensitization.Psychopharmacology · 2020Article
- MDMA-assisted psychotherapy for people diagnosed with treatment-resistant PTSD: what it is and what it isn't.Annals of general psychiatry · 2020Review
- Neuroscience Informed Prolonged Exposure Practice: Increasing Efficiency and Efficacy Through Mechanisms.Frontiers in behavioral neuroscience · 2018Article
- The reconsolidation using rewind study (RETURN): trial protocol.European journal of psychotraumatologyArticle
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present paper discusses the current literature with regard to substance-assisted psychotherapy with Methylenedioxymethamphetamine (MDMA) for posttraumatic stress disorder (PTSD). The aim of the paper is to give a comprehensive overview of the development from MDMA's early application in psychotherapy to its present and future role in the treatment of PTSD. It is further attempted to increase the attention for MDMA's therapeutic potential by providing a thorough depiction of the scientific evidence regarding its theorized mechanism of action and potential harms of its application in the clinical setting (e.g., misattribution of therapeutic gains to medication instead of psychological changes). Empirical support for the use of MDMA-assisted psychotherapy, including the randomized, double-blind, placebo-controlled trails that have been conducted since 2008, is discussed. Thus far, an overall remission rate of 66.2% and low rates of adverse effects have been found in the six phase two trials conducted in clinical settings with 105 blinded subjects with chronic PTSD. The results seem to support MDMA's safe and effective use as an adjunct to psychotherapy. Even though preliminary studies may look promising, more studies of its application in a psychotherapeutic context are needed in order to establish MDMA as a potential adjunct to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.